Trial Profile
A Single-arm, Multicenter, Open-label, 52-week Treatment, Extension Study to CLDT600ACN04 Study to Evaluate the Efficacy (Including Histological Improvement) and Safety in Fourth to Sixth Year of Telbivudine Treatment in Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2017
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 29 Jun 2017 New trial record